Functional interactions between the paraventricular hypothalamic nucleus and raphe magnus. A comparative study of an integrated homeostatic analgesic mechanism.

Condés-Lara M, Rojas-Piloni G, Martínez-Lorenzana G, Diez-Martínez DC, Rodríguez-Jiménez J

Neuroscience22 Feb 2012Cited by 18 (Europe PMC)

PMID22390942DOI10.1016/j.neuroscience.2012.02.032PepBankPUB-22390942

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01AnimalEndogenous levelAnimal study (in vivo)Mechanism
In an animal model, immunohistochemistry confirmed oxytocinergic innervation in the projection from the paraventricular nucleus to the raphe magnus.
In plain wordsIn animals, tissue staining showed that the body's own oxytocin nerve fibres run from a brain region to the raphe magnus.
Peptide
Oxytocin
Outcome
Not applicableOxytocinergic innervation of the PVN projection to the raphe magnus
Study
n: not reported in source
Outcome group
Pain · Nervous system and cognition
Source sentences
Summary
the immunohistochemical experiments confirmed the oxytocinergic and the vasopresinergic innervation used by the PVN projection to the RMg
1 context sentence(design, population, supporting numbers)
Summary · context
This work compares the effects of electrical stimulation of the paraventricular hypothalamic nucleus (PVN) and the raphe magnus nucleus (RMg) on the single-unit response from dorsal spinal cord neurons activated by nociceptive receptive field stimulation.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2239094202

Studies that did not test the peptide alone1

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

02AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Mechanism
In an animal model, an intrathecal oxytocin antagonist strongly reduced the suppressive effect of paraventricular nucleus stimulation on spinal cord neuron responses.
In plain wordsIn animals, blocking the oxytocin receptor in the spinal cord strongly reduced the pain-signal suppression caused by stimulating a brain region.
Peptide
Oxytocin
Outcome
DecreasePVN stimulation suppression of spinal cord neuron responses after oxytocin antagonist
Study
n: not reported in source
Outcome group
Pain · Nervous system and cognition
Source sentences
Summary
The intrathecal administration of 20 μl of a 10⁻⁵ M solution of a specific oxytocin antagonist strongly reduced the PVN effects
1 context sentence(design, population, supporting numbers)
Summary · context
This work compares the effects of electrical stimulation of the paraventricular hypothalamic nucleus (PVN) and the raphe magnus nucleus (RMg) on the single-unit response from dorsal spinal cord neurons activated by nociceptive receptive field stimulation.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-2239094201

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 01:30 UTC
Study results updated
Version 1
9 Oct 2026, 02:52 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.